FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia

Leukemia · Published 2026-06-30 · DOI 10.1038/s41375-026-03030-0

Free full text

Authors (27)

Clarissa Garcia, Kaylyn U. Lyons, Julian Grandvallet Contreras, Tian Liu, Alexis J. Donnelly, Amanda J. Novak, Amy Argabright, Colin C. Anderson, Abby Grier, Sabrina Smith, Joshua Michlin, Jesutomisin Olusoji, Railey G. Mikeska, Xin Zhou, Huimin Geng, Jeremy T. Rahkola, Hiten N. Patel, Jeffrey G. Jacot, Markus Müschen, Angelo D'Alessandro, John E. Dick, Ilaria Iacobucci, Charles G. Mullighan, Julie A. Reisz, Tzu Phang, M. Eric Kohler, Matthew T. Witkowski

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Garcia, C., Lyons, K., Contreras, J., et al. (2026). FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. Leukemia. https://doi.org/10.1038/s41375-026-03030-0

Related articles

• Evolutionary considerations for risk stratification in TP53-variant myeloproliferative neoplasms · Leukemia · 2026 · Same journal
• Rbm5 sustains leukemia stem cells through a Myc-driven transcriptional circuitry · Leukemia · 2026 · Same journal
• Cohesin haploinsufficiency and inv(16) cooperate to reinforce Fli1 gene transcriptional programs during acute myeloid leukemia initiation and maintenance · Leukemia · 2026 · Same journal
• Non-invasive multiparametric characterization of essential thrombocythemia, premyelofibrosis, and overt myelofibrosis · Leukemia · 2026 · Same journal
• IKZF1N159S is associated with adverse outcomes in patients with myelodysplastic neoplasms · Leukemia · 2026 · Same journal
• Tumor molecular age acceleration is associated with early progression in diffuse large B-cell lymphoma · Leukemia · 2026 · Same journal
• Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry · Leukemia · 2026 · Same journal
• Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms · Leukemia · 2026 · Same journal
• Stuck in traffic: CART cells targeting the tumor microenvironment in hematological malignancies, current advances and future perspectives · Leukemia · 2026 · Same journal
• Unpacking the epigenetic landscape of acute lymphoblastic leukemia: resolving cellular heterogeneity and nutritional complexities · Leukemia · 2026 · Same journal